New anticoagulants

Area of Science:

• Pharmacology and Therapeutics
• Hematology
• Drug Development

Background:

• Current anticoagulants like heparins and vitamin K antagonists have limitations, including narrow therapeutic windows and the need for frequent monitoring.
• Vitamin K antagonists, the only approved oral anticoagulants, require regular international normalized ratio (INR) monitoring and dose adjustments.

Purpose of the Study:

• To review the development and status of novel anticoagulants that selectively inhibit thrombin or factor Xa.
• To discuss the challenges in designing clinical trials for these new agents compared to existing anticoagulants.

Main Methods:

• Review of randomized clinical trials and advanced clinical development phases for new anticoagulants.
• Analysis of fondaparinux's efficacy compared to low-molecular-weight heparin.
• Examination of challenges in designing pivotal clinical trials for novel antithrombotic agents.

Main Results:

• Fondaparinux, a synthetic pentasaccharide, indirectly inhibits factor Xa and has demonstrated efficacy in preventing and treating venous thromboembolism.
• Oral direct factor Xa inhibitors and oral direct thrombin inhibitors are in late-stage clinical development for thrombosis prevention and treatment.
• Selective inhibitors show predictable dose-response relationships, unlike current anticoagulants.

Conclusions:

• Selective coagulation factor inhibitors have the potential to be more effective, safer, and easier to use than current anticoagulants.
• The approval of new selective anticoagulants is expected to enhance the therapeutic options for managing thrombosis.